Correction: Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25–69 years living in Australia
ثبت نشده
چکیده
Acknowledgments We would like to thank the following associate investigators for their contribution to the Compass trial: Mr David H Wrede, Dr Jeff Tan, Dr Siobhan Bourke, Dr Lara Roeske, Dr Jane Collins, Sandy Anderson and Associate Professor Sally Lord. We would also like to acknowledge the following Scientific Advisory Committee members: Professor Bruce Armstrong, Professor Suzanne Garland, Professor Jonathan Carter, Associate Professor Rachel Skinner, Dr Deborah Bateson, Professor Andrew Grulich, Dr Eduardo Franco, Ms Bridget Whelan (sadly deceased), Associate Professor Annabelle Farnsworth and Ms Susan Taylor. In addition, we would like to acknowledge the following members of the Independent Data Safety and Monitoring Committee: Professor Michael Quinn, Associate Professor Katrina Sharples, Dr Penny Blomfield, Dr Gordon Wright and the secretariat at NHMRC Clinical Trials Centre. Finally, we would like to thank Dr David Hawkes and Ms Chloe Jennett for their contribution to the trial and Dr Louiza S Velentzis for coordinating the authoring of this manuscript.
منابع مشابه
Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25–69 years living in Australia
INTRODUCTION Australia's National Cervical Screening Program (NCSP) currently recommends 2-year cytology in women aged 18-69 years. Following a review of the NCSP prompted by the implementation of human papillomavirus (HPV) vaccination, the programme will transition in 2017 to 5-year primary HPV screening with partial genotyping for HPV16/18 in women aged 25-74 years. Compass is a sentinel expe...
متن کاملCost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.
BACKGROUND The availability of human papillomavirus (HPV) DNA testing and vaccination against HPV types 16 and 18 (HPV-16,18) motivates questions about the cost-effectiveness of cervical cancer prevention in the United States for unvaccinated older women and for girls eligible for vaccination. METHODS An empirically calibrated model was used to assess the quality-adjusted life years (QALYs), ...
متن کاملCervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial
BACKGROUND Using primary human papillomavirus (HPV) testing for cervical screening increases detection of high-grade cervical intraepithelial neoplastic lesions and invasive cancer (cervical intraepithelial neoplasia grade 2+ [CIN2+]) compared to cytology, but no evaluation has been conducted in a population previously offered HPV vaccination. We aimed to assess colposcopy referral and CIN2+ de...
متن کاملEffectiveness Modelling and Economic Evaluation of Primary HPV Screening for Cervical Cancer Prevention in New Zealand
BACKGROUND New Zealand (NZ) is considering transitioning from 3-yearly cervical cytology screening in women 20-69 years (current practice) to primary HPV screening. We evaluated HPV-based screening in both HPV-unvaccinated women and cohorts offered HPV vaccination in New Zealand (vaccination coverage ~50%). METHODS A complex model of HPV transmission, vaccination, cervical screening, and inva...
متن کاملThe clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
BACKGROUND The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial originally reported after two rounds of primary cervical screening with human papillomavirus (HPV). Extended follow-up of the randomised trial cohort through a third round could provide valuable insight into the duration of protection of a negative HPV test, which could allow extended screening intervals. If HPV...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 8 شماره
صفحات -
تاریخ انتشار 2018